Search
Search
#1. Three-year Efficacy and Safety of Takeda's Dengue Vaccine ...
Takeda's tetravalent dengue vaccine (TAK-003), a live attenuated vaccine based on a DENV-2 backbone [5], is the most advanced among the ...
TAK -003 is a live attenuated tetravalent dengue vaccine, preventing dengue fever caused by any of the four serotypes of the dengue virus produced by Takeda ...
#3. Potential Impact of Takeda's Dengue Vaccine Candidate ...
Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “ ...
#4. Three years efficacy and safety of Takeda's dengue vaccine ...
TAK -003 was efficacious against symptomatic dengue over three years. Efficacy declined over time but remained robust against hospitalized ...
#5. Current Development and Challenges of Tetravalent Live ...
Takeda's dengue vaccine (TAK-003) candidate is based on the molecularly characterized live attenuated DENV-2 PDK-53 strain (TDV-2).
#6. Efficacy of the TAK-003 Vaccine for Protection Against ...
The researchers concluded that the TAK-003 vaccine effectively protected children and adolescents against dengue fever and was associated with a ...
#7. Efficacy, Safety and Immunogenicity of Takeda's Tetravalent ...
The vaccine being tested in this study is Takeda's Tetravalent Dengue Vaccine Candidate (TDV). TDV is being tested to protect people against dengue fever and to ...
#8. tak-003-fact-sheet-11.22.19.pdf - Takeda Vaccines
Takeda is developing a live-attenuated tetravalent dengue vaccine candidate (TAK-003) to help address unmet needs in dengue prevention.
#9. Potential Impact of Takeda's Dengue Vaccine ... - Taiwan News
Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic " ...
#10. Characterization of the cell-mediated immune response to ...
The tetravalent dengue vaccine candidate, TAK-003 (Takeda Vaccines), is based on a live attenuated DENV-2 virus (TDV-2) that provides the ...
#11. Efficacy of a dengue vaccine candidate (TAK ... - Europe PMC
Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents ... Takeda's dengue vaccine is under evaluation in an ongoing Phase 3 ...
#12. Dengue vaccine - Wikipedia
In March 2021, the European Medicines Agency accepted the filing package for vaccine candidate TAK-003, which is designated for people not ...
#13. Takeda's dengue vaccine efficacy slips between 12 - Fierce ...
In a new 18-month data analysis from the study released over the weekend, Takeda's TAK-003 was 73.3% effective overall. Within that number, efficacy figures for ...
#14. GDAC statement on Takeda's announcement about their ...
GDAC statement on Takeda's announcement about their Dengue vaccine phase 3 efficacy trial ... TAK-003 was found to be efficacious among trial participants in ...
#15. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children ...
In conclusion, TAK-003 was efficacious against virologically confirmed dengue fever among healthy children and adolescents 4 to 16 years of age, ...
#16. Immunogenicity and safety of a tetravalent dengue vaccine in ...
Objective To describe the immunogenicity and safety of a tetravalent dengue vaccine (TAK-003) in healthy adolescents living in Mexico City, ...
#17. Tetravalent Dengue Vaccine (TAK-003) Development Program
PDF | Background Dengue fever is a mosquito-borne viral disease endemic in 128 countries. An unmet clinical need remains for an effective ...
#18. Long-Term Study Reaffirms Potential of Takeda's Dengue ...
TAK0-003, a tetravalent dengue vaccine candidate, is based on a live-attenuated dengue serotype 2 virus. In Phase I and II trials, children and ...
#19. For India, Finally A Dengue Vaccine In Sight | Mint
If approved, Takeda's TAK-003 will be the first dengue vaccine to be cleared for use in India. The vaccine prevented severe disease in ...
#20. Takeda's dengue vaccine bags positive long-term efficacy ...
Japanese pharma company Takeda has announced that its dengue vaccine candidate TAK-003 demonstrated continued protection through three years ...
#21. EMA accepts submission for Takeda's dengue vaccine ...
TAK -003 is a tetravalent dengue vaccine candidate based on a live-attenuated dengue serotype 2 virus, which provides the genetic backbone for ...
#22. Planning ahead for access to the dengue vaccine
Takeda has strong project-specific access plans for some late-stage R&D projects. One such project is its dengue vaccine (TAK-003). Takeda intends to file for ...
#23. TAK 003 - AdisInsight
TAK 003 (previously called DENVax™), a tetravalent hybrid virus vaccine, is being developed by Takeda Pharmaceuticals USA, for the prevention of dengue ...
#24. After Sanofi's setbacks, Takeda eyes finish line with its dengue ...
Three-year data with Takeda dengue vaccine TAK-003 reinforces efficacy and safety as it plans additional filings, and a showdown with ...
#25. Dengue endemic vaccines: awaiting Takeda's TAK-003
A Sanofi Pasteur vaccine (CYD-TDV Dengvaxia®) has been licensed since 2015 for the prevention of disease caused by all four dengue virus ...
#26. Takeda's dengue vaccine prevents hospitalisations in TIDES ...
Takeda's tetravalent dengue vaccine candidate, TAK-003, offers protection against hospitalisation and illness in Phase III trial.
#27. 武田登革热候选疫苗(TAK-003) 的三年疗效和安全性 - X-MOL
Background Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across ...
#28. Takeda's dengue vaccine efficacious, decreases ...
Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) will be the first dengue vaccine to be cleared for use in India if ...
#29. CYD-TDV, TDV (TAK-003), and TV003/TV005 - e-journal unair
由 YJ Hertanto 著作 · 2021 — One licensed dengue vaccine is CYD-TDV (Dengvaxia). Abstract: Dengue fever is the most common tropical disease, but there still remains no ...
#30. New dengue vaccine performs well in large trials - SBMT
An experimental dengue vaccine called TAK-003, showed promising initial results in a large study in several countries. Manufactured by the Takeda ...
#31. Takeda Still Hopeful On Dengue Vaccine Candidate - Pink ...
Takeda Pharmaceutical hopes to find out by the end of fiscal year 2021 whether its tetravalent dengue vaccine candidate, TAK-003, is likely to ...
#32. Current Development and Challenges of ... - DSpace@MIT
Takeda's dengue vaccine (TAK-003) candidate is based on the molecularly characterized live attenuated DENV-2 PDK-53 strain (TDV-2). Three other ...
#33. Defining levels of dengue virus serotype-specific ... - PLOS
TAK -003 is a tetravalent live attenuated dengue vaccine candidate developed by Takeda Vaccines Inc, which is currently being evaluated in phase ...
#34. Global Dengue Fever Pipeline Insights | Clinical Trials
In May 2021, Takeda Pharmaceutical Company Limited announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection ...
#35. Scientists Announce Promising New Dengue Vaccine - NPR
In results just published in the New England Journal of Medicine, Wallace and his colleagues found TAK-003 to be 80% effective in preventing ...
#36. Efficacy of a tetravalent dengue vaccine in ... - The Lancet
The Takeda tetravalent dengue vaccine candidate (TAK-003) was originally designed and constructed by scientists at the Division of Vector- ...
#37. Takeda begins regulatory submissions for ... - Bangkok Post
... announced that the European Medicines Agency (EMA) has accepted the Company's filing packages for its dengue vaccine candidate (TAK-003) ...
#38. Takeda's dengue data spell more bad news for Sanofi | Evaluate
Takeda's pivotal trial has suggested that TAK-003 could work in both dengue-naïve and previously infected patients, making Sanofi's ...
#39. Medline ® Abstract for Reference 35 of 'Dengue virus infection
We assessed the immunogenicity and safety of three different dose schedules of a tetravalent dengue vaccine (TAK-003) over a 48-month period in children ...
#40. 3-year mark for Takeda Dengue vaccine: efficacy remains with ...
Ongoing data demonstrate TAK-003 vaccine candidate efficacy against symptomatic dengue virus (DENV) in both children and adolescents 3 years ...
#41. TAK-003 - PMLiVE
Dengue vaccine TAK -003:Takeda's dengue fever vaccine candidate TAK-003 hit the efficacy mark in a large-scale study reported earlier this month, ...
#42. Dengue vaccine shows promising results at 18 months - Healio
The findings are from a planned 48-month trial analyzing the safety and immunogenicity of the vaccine candidate, TAK-003, in children living ...
#43. Takeda dengue vaccine meets main goal of trial - Reuters
While Sanofi's vaccine was based on a Yellow fever virus with dengue genes added in, TAK-003 is based on a weakened dengue 2 virus plus ...
#44. Outside EU/EEA - Clinical Trials Register
D.3 Description of the IMP. D.3.1, Product name, Tetravalent Dengue Vaccine Candidate (TDV). D.3.2, Product code, TAK-003.
#45. Takeda's Elke Walter & Derek Wallace Share Insights on TAK ...
Derek Wallace: We presented data from our dengue and Zika vaccine ... the second dose) across five trials of Takeda's dengue vaccine candidate, TAK-003.
#46. Dengue Vaccines For 2022 - Vax Before Travel
TAK -003 is an investigational live-attenuated tetravalent dengue vaccine that prevents dengue fever caused by any of the four dengue virus serotypes, ...
#47. TAK-003 induces functional DENV cross-reactive cellular ...
Dengue virus (DENV) transmitted by Aedes aegypti causes dengue fever (DF), dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). DENV infection ...
#48. Takeda Begins Regulatory Submissions for ... - Financial Post
European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda's Dengue Vaccine Candidate (TAK-003), ...
#49. Dengue Vaccines: Current Status and Future Prospects - JCDR
DenVax: This vaccine, also known as TAK-003, has been developed by Takeda, Osaka, Japan [12]. This live-attenuated tetravalent dengue vaccine ...
#50. Dengue Vaccine Protects Youth | Adolescent Medicine - JAMA ...
The most recent trial results of the new vaccine candidate, TAK-003, in about 20 000 young study participants suggest that its overall ...
#51. Takeda Begins Regulatory Submissions for ... - Vietnam News
European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda's Dengue Vaccine Candidate (TAK-003), ...
#52. What You Need To Know About Takeda's Dengue Vaccine
TAK -003 is based on a dengue serotype 2 virus which provides the genetic 'backbone' for all four vaccine viruses. Phase III clinical trials ...
#53. Takeda signals global ambitions with dengue vaccine trial
TAK -003 will compete against a new dengue vaccine from Sanofi of France, which has completed its clinical trials. Sanofi recently launched the ...
#54. #VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in ...
1. In part 1, phase 3 of this randomized controlled trial, the overall vaccine efficacy of TAK-003 (dengue vaccine candidate) was ...
#55. New dengue vaccine candidate shown to be safe, effective 3 ...
A new dengue vaccine candidate, TAK-003, has demonstrated the persistence of neutralizing antibodies in participants who were inoculated ...
#56. Dengue Vaccine Candidate Provides 62% Efficacy for ...
TAK -003, from Takeda, is showing slightly improved protection among seropositive participants through its 36-month follow-up.
#57. Takeda Initiates Global Phase 3 Clinical Trial for Dengue ...
... a Phase 3 double-blind, randomized and placebo-controlled trial of its live-attenuated tetravalent dengue vaccine candidate (TAK-003).
#58. Dengue vaccine from Takeda shows promise - News Medical
The latest dengue vaccine TAK-003 is manufactured by the Takeda Pharmaceutical Company. Derek Wallace from Takeda said in a statement, ...
#59. Takeda dengue vaccine meets main goal of clinical trial
The company said no significant safety concerns have emerged to date with vaccine called TAK-003. Takeda did not disclose how the vaccine ...
#60. Takeda to Submit Regulatory Filing for New Dengue Vaccine ...
Today, there are five dengue vaccine candidates in clinical development, WHO said. Takeda's TAK-003 and another one developed by the US ...
#61. ACIP Dengue Vaccines Workgroup Considerations and ... - CDC
Workgroup Considerations: Dengvaxia Acceptability in ... a tetravalent dengue vaccine candidate (TAK-003) in regions of Asia and Latin ...
#62. Dengue Vaccine: Takeda Reports Promising Results
In a press release, Takeda announced that its vaccine candidate, TAK-003, reduced illnesses from dengue by 62% and prevented 83.6% of ...
#63. Vaccines and immunization: Dengue - WHO | World Health ...
Vaccines and immunization: Dengue. 20 April 2018 | Q&A. What is the current status of dengue vaccine development?
#64. Takeda Says Its Dengue Vaccine Candidate Prevents Illness ...
Takeda's dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalisations and 62.0% of dengue illness overall, with no identified ...
#65. Takeda files long-term dengue vaccine data to support EU ...
New three-year safety and efficacy data on Takeda Pharmaceutical Co. Ltd.'s dengue vaccine candidate, TAK-003, showed it to be 62% more ...
#66. EU evaluates Takeda's dengue vaccine candidate
“Sending regulatory records to our dengue vaccine candidate, TAK-003, marks an important development for people living in or traveling to ...
#67. Dengue vaccine: an update - Taylor & Francis Online
dengue vaccine, CYD-TDV (Dengvaxia®), and two second- generation vaccines in phase 3 studies, TAK-003 (DENVax) and TV003/TV005 (U.S. ...
#68. Dengue Vaccine Candidate Reinforced by Long-Term Safety
REPUBLIKA.CO.ID, JAKARTA -- Takeda Pharmaceutical Company Limited (Takeda) announced that its dengue vaccine candidate (TAK-003) ...
#69. With its dengue vaccine in the regulatory queue, Takeda ...
Having followed 20,000 study participants for 36 months after their second dose of TAK-003, investigators reported that vaccine efficacy ...
#70. Enhanced dengue vaccine virus replication and neutralizing ...
Three DENV live attenuated vaccines (LAV) are in advanced stages of development: TV003/TV005 from the U.S. National Institutes of Health, TAK- ...
#71. Dengue Vaccine Candidate TAK-003 Looks Promising ... - MPR
TAK -003 is based on a live-attenuated dengue serotype 2 virus. The TIDES trial is investigating the safety and efficacy of 2 doses of TAK-003 in ...
#72. Safety, Immunogenicity, and Efficacy of a Tetravalent Dengue ...
The tetravalent dengue vaccine TAK-003 (Takeda Vaccines, Inc.) is based on a live-attenuated dengue serotype-2 virus (DENV-2) that provides ...
#73. EMA accepts Takeda's regulatory filing for dengue vaccine ...
“Submission of regulatory filings for our dengue vaccine candidate, TAK-003, marks an important development for people who are living in or ...
#74. Takeda's TAK-003 dengue vaccine candidate succeeds in ...
Takeda investigational dengue vaccine (TAK-003) candidate has achieved the primary endpoint in the pivotal phase 3 efficacy trial.
#75. Takeda's Dengue Vaccine Manufacturing Plant, Singen
... Pharmaceuticals opened a new vaccine manufacturing plant in Singen, Germany for the production of its dengue vaccine candidate, TAK-003.
#76. Efficacy of a Dengue Vaccine Candidate ... - Oxford Academic
Takeda's tetravalent dengue vaccine (TAK-003) continued to demonstrate benefit in reducing dengue independent of baseline serostatus up to 2 years after ...
#77. Defining levels of dengue virus serotype-specific ... - bioRxiv
Here, we mapped the specificity of antibodies induced by the Takeda tetravalent dengue vaccine TAK-003 in monkeys and humans with no prior ...
#78. Takeda dengue vaccine candidate show long term safety ...
Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “ ...
#79. New dengue vaccine being created: Here's what we know ...
Scientists are making final tweaks in the formula for a new dengue vaccine called TAK-003 which will be able to help in preventing the spread of ...
#80. Hopeful results from trials of dengue vaccine candidate
Vaccine effectiveness was 80.2% in the first 11 months and 73.3% in the first 17 ... Effectiveness for TAK-003 varied by serotype (dengue 1, ...
#81. Takeda Pharmaceutical's dengue vaccine shows promise in ...
#82. Takeda Symposium | Asian Dengue Voice and Action - ADVA ...
3.1.4 TAK-003 Efficacy and Safety: phase 3 clinical study, by Dr Walid Kandeil. play. 3.1.5 Vaccine Hesitancy, by Professor Tikkit Pangestu.
#83. The Impact of Serotype Cross-Protection on Vaccine Trials ...
Two tetravalent dengue vaccines, Dengvaxia (CYD-TDV—Sanofi Pasteur) and DENVax (TAK 003—Takeda Pharmaceutical Company), have now completed phase 3 clinical ...
#84. First Presentation of Long-Term Safety & Efficacy Data for ...
First Presentation of Long-Term Safety & Efficacy Data for Dengue Vaccine Candidate. Watch later. Share. Copy link.
#85. New dengue vaccine effective in clinical trials - Asia & Pacific
“Our dengue vaccine candidate, TAK-003, is based on a live-attenuated dengue serotype 2 virus (DENV-2), which provides the genetic ...
#86. Potential Impact of Takeda's Dengue Vaccine Candidate ... - QLifePro
Through three years (36 months after the second dose), TAK-003 demonstrated overall vaccine efficacy (VE) of 62.0% (95% CI: 56.6% to 66.7%) against ...
#87. First vaccine for prevention of dengue - European Medicines ...
Dengue is caused by a virus which is transmitted by Aedes mosquitoes, a type of mosquito that is widely spread in tropical and subtropical ...
#88. takeda news. CNBC News on Google+: http://cnb., which also ...
TAK: Get the latest Takeda Pharmaceutical stock price and detailed information including ... The latest dengue vaccine TAK-003 is manufactured by the Takeda ...
#89. Dengue Vaccine Sales Market Size 2022 Segments ...
Dengue Vaccine Sales Market Size 2022 Segments, Competitors Strategy, ... CYD-TDV; DENVax or TAK-003; TetraVax-DV; TDENV PIV; V180; DNA vaccines. Dengue ...
#90. Dengue Virus-Specific T Cell Immunity - 第 163 頁 - Google 圖書結果
The other two dengue vaccines in development are based on full length DENV. One [Takeda, tetravalent dengue vaccine (TAK-003)] uses an attenuated strain of ...
#91. Dengue Vaccine Market Report 2022 – Players, Countries ...
The recent report on “Dengue Vaccine Market” offered by Credible Markets, comprises of a comprehensive investigation ... DENVax or TAK-003
#92. Sewing Patterns and Ideas — CraftBits. - companionanimals.de
Get the latest Takeda Pharmaceutical Company Limited (TAK) stock news and headlines to ... The latest dengue vaccine TAK-003 is manufactured by the Takeda ...
#93. GlaxoSmithKline, Merck Sharp & Dohme, Sanofi - Sportlepsia
Segmentación del mercado Vacuna contra el dengue global: Segmentación del mercado: por tipo. CYD-TDV, DENVax o TAK-003, TetraVax-DV, ...
#94. Le Vaccin Contre La Dengue D'Un Marché Mondial De L ...
Le rapport sur le marché Le Vaccin Contre La Dengue fournit un aperçu détaillé des… ... DENVax ou TAK-003 TetraVax-DV TDENV PIV V180 les vaccins à ADN.
#95. Mercado mundial de vacunas contra el dengue Desarrollo ...
Mercado global de vacuna contra el dengue dividido por tipo: CYD-TDV DENVax o TAK-003 TetraVax-DV TDENV PIV V180 vacunas de ADN.
#96. Investigación, Ingresos Y Pronóstico Del Mercado Global De ...
Vacuna contra el dengue es un documento de mercado profesional y ... CYD-TDV, DENVax o TAK-003, TetraVax-DV, TDENV PIV, V180, vacunas de ADN.
#97. Cooling the Hype on the '100% Effective' Dengue Vaccine
Researchers at the National Institutes of Health, Johns Hopkins University, and the University of Vermont developed the vaccine, called TV003, ...
tak-003 dengue vaccine 在 First Presentation of Long-Term Safety & Efficacy Data for ... 的推薦與評價
First Presentation of Long-Term Safety & Efficacy Data for Dengue Vaccine Candidate. Watch later. Share. Copy link. ... <看更多>